CORE--TISSUE CHARACTERIZATION AND IMMUNOREAGENT RESOURCE

常染色体隐性遗传性PKD小鼠模型的分子机制研究 (ARPKD)将需要对肾、胆管和肝脏组织进行专业的形态和免疫组织化学分析，获得最先进的分子分析来评估ARPKD细胞，并开发新的免疫反应剂来探索ARPKD细胞的调节。这一核心的目标是通过以经济高效的方式在一个单一的统一平台上协调三个成熟的UAB核心设施，为ARPKD组织和细胞的分子分析提供全面的一系列服务，以最大限度地提高可访问性，优化方案，并为当地和扩展的ARPKD研究基地提供培训。组织表征和免疫反应剂资源(TCIR)核心将为处理小鼠组织提供集中和受控的设施，以进行形态和组织化学分析、免疫组织化学方案优化和定量形态计量分析。此外，P30调查人员将获得激光捕获等先进技术 显微解剖(LCM)、荧光共振能量转移(FRET)显微镜和原位 杂交。TCIR核心的表位识别和免疫反应组件(ERIC)将协助P30研究人员开发与PKD研究相关的新型单抗试剂(杂交瘤和抗体噬菌体展示技术)，并作为常用单抗的生产和分配中心。TCIR的总体目标是：特定目标1-提供由研究人员提供的准确、可重复和标准化的动物组织光镜病理学专家解释。特定目的2-为P30研究人员提供需要复杂特殊技术的动物组织的处理和数据积累，包括形态测量、定量PCR、原位杂交、免疫组织化学、透射电子显微镜、激光捕获显微切割和FRET活细胞成像。特定目的3-为PKD研究人员提供杂交瘤和抗体噬菌体展示技术方面的专业知识，以促进与ARPKD研究相关的新型或已建立的克隆试剂的生产和销售。 具体目标4--通过对消耗品的集中采购和库存管理来提高成本效益，并有效地执行当地和扩展研究基地所要求的质量控制和质量保证活动。

Understanding the molecular mechanisms underlying mouse models of autosomal recessive PKD (ARPKD) will require expert morphological and immunohistochemical analysis of renal, biliary, and hepatic tissues, access to state of the art molecular analyses for assessment of ARPKD cells, and generation of novel immunoreagents to probe ARPKD cell regulation. The goal of this Core is to provide a comprehensive array of services for molecular analysis of ARPKD tissues and cells through the coordination of three well-established UAB Core facilities in a single unified platform in a cost-effective manner to maximize accessibility, to optimize protocols, and to provide training for the local and extended ARPKD research base. The Tissue Characterization and Immunoreagent Resource (TCIR) Core will provide a centralized and controlled facility for processing of mouse tissues for morphologic and histochemical analysis, optimization of immunohistochemical protocols, and quantitative morphometric analysis. In addition, P30 investigators will have access to advanced technologies such as Laser Capture Microdissection (LCM), fluorescence resonance energy transfer (FRET) microscopy, and in situ hybridization. The Epitope Recognition and Immunoreagent Component (ERIC) of the TCIR Core will assist P30 investigators in the development of novel monoclonal reagents (hybridoma and antibody phage display technology) with relevance to the study of PKD and also serve as a production and distribution center for commonly utilized monoclonal antibodies. The overall objectives of the TCIR are: SPECIFIC AIM 1 - To provide accurate, reproducible, and standardized expert light microscopic pathologic interpretation of animal tissues provided by investigators. SPECIFIC AIM 2 - To provide for the processing and data accumulation to P30 investigators of animal tissues requiring sophisticated special techniques including morphometry, quantitative PCR, in-situ hybridization, immunohistochemistry, transmission electron microscopy, laser capture microdissection, and FRET live cell imaging. SPECIFIC AIM 3 -Provide PKD investigators with expertise in hybridoma and antibody phage display technology to facilitate production and distribution of novel or established monoclonal reagents related to the study of ARPKD. SPECIFIC AIM 4 -To enhance cost effectiveness by centralized purchasing and inventory management of consumable supplies and to efficiently perform quality control and quality assurance activities required by the local and extended research base.